Ten COVID-19 vaccines seen by mid-year, head of global pharma group says


Ten COVID-19 vaccines seen by mid-year…
Here are the best iPad deals right now
Exclusive: VW CEO pushes for contr…
How to stay positive during the Covid-19…
Instant Pot Appliances Are Seriously Marked…
Best & Worse 2022 World Cup Qualif…
Volvo S60 bookings to open in January 2021
US air traffic on Thanksgiving Eve…
John Boyega scoops Icon prize at 2020 GQ…
Activists, Black celebrities call on UK…
The best Black Friday deals happening now
Greedfall is coming to PS5, Xbox Series X…
STI Investing reaches $2b milestone
Americans celebrate Thanksgiving under…
This Is the Oldest Fast-Food Chain In America
The Manchester City Lineup That Should…
Nissan India widens footprint with 50 new…
Feasts and holy days in the Kazakhstan desert
Thai Airways to bomb Thailand with prayers…
Experts May Have Found The Best Way…
Brexit deal on Gibraltar still possible: chief…
The best Black Friday deals under $50
Black Friday gaming monitor deals 2020…
For Big Tech, Biden brings a new era but…
Are Your Periods Irregular or Even …
Lamborghini Huracan STO: Now in pictures
Why The GoPro Hero 9 Black Is Your Action
Kristen Stewart Feels ‘Protective’ of Princ…
Tommy Hilfiger shares the secrets to his…
Thai pro-democracy protesters warn of…
International coalition of activists launches…
The best Black Friday deals under $50
Billionaire to open family office in SG
What ‘Happiest Season’ Gets Right & Wrong…
Great British Bake Off’s Prue Leith Is The…
Diego Maradona perfectly summed up…
Designer Daniel W Fletcher: Harry Styles had a huge impact on my career
Here are the best iPad deals right now
GENEVA (Reuters) – Ten COVID-19 vaccines could be available by the middle of next year if they win regulatory approval, but their inventors need patent protection, the head of the global pharmaceutical industry group said on Friday.
Vaccines by Pfizer and BioNtech, as well as Moderna and AstraZeneca have shown promising results in large clinical trials, but there is no question of “cutting corners”, said Thomas Cueni, director-general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
“So far 3 we have 3 out of 3 were hits. I would expect that we will see something similar with Johnson & Johnson, I would expect that we would see similar positive results with Novavax, and many others, Sanofi Pasteur, GSK are in there, Merck,” he said.
‘Big Pharma’ and biotech firms have invested heavily in research and development and in boosting manufacturing during the pandemic to be able to roll out vaccine doses, Cueni told a Geneva news briefing.
It would be a mistake to lift patent protection to allow compulsory licensing and try to make vaccines requiring such complex quality assurance without expert staff and quality control procedures, he said.
“We will hopefully by the next summer have probably 10 vaccines which have proven their value. But all of them really need to be submitted by rigorous scientific scrutiny by the regulators.”
At the World Trade Organization (WTO), India and South Africa have proposed allowing a temporary waiver to allow compulsory licensing for patented products during the pandemic. The United States, European Union and Switzerland and others have rejected it, trade officials say.
Cueni, asked about the proposal, said: “For me this questioning of IP is really primarily politics, but it’s politics which is not helpful because it would send very negative signals in terms of disrespect to the system which allowed the world to react so fast and so responsibly.”
Vaccine manufacturing plants often need 50 quality assurance staff making hundreds of checks during production, he said, emphasising that the companies would not exploit the pandemic.
Cueni said that IFPMA archives showed there had never been a compulsory license granted for a vaccine and pointed to the difficult technology and know-how. Nearly every member company had committed to “not-for-profit” or socially responsible pricing during the pandemic, he added.
(Reporting by Stephanie Nebehay and Philippa Fletcher)
Young Trader Has Quietly Made Over $2.8MM In 2020
diagnostic code reader

Comments are closed, but trackbacks and pingbacks are open.